A Phase 3, Multicenter, Randomized, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (IDeate-2)

Protocol No

DAIICHI-DS7300-188

Staff Member

Hui-Zi Chen

Phase

III

Summary

This project is being done to find out whether an investigational drug for SCLC, Ifinatamab Deruxtecan (or I-DXd), is better than amrubicin, lurbinectedin, and topotecan (collectively, these standard treatments are called “treatment of physician’s choice” or TPC), a routine treatment for SCLC.

Objective

Study of ifinatamab deruxtecan in subjects with relapsed small cell lung cancer

Study Sites

Froedtert Hospital

Status

ON HOLD